A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer: The VIOLETTA Trial
A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer Using Organ Based Tracking (OBT) Navigation: The VIOLETTA Trial
This study is to investigate the efficacy of Targeted Microwave Ablation (TMA) under MRI-Ultrasound fusion and organ-based tracking (OBT) navigation in localized prostate cancer (PCa) in a multi-centre trial.
調査の概要
状態
条件
詳細な説明
This is a prospective multi-centre trial in 5 hospitals in 4 countries to investigate the efficacy and complications of TMA as a minimally invasive focal therapy for PCa. Men aged ≥50 with PSA < 20ng/mL, 1-2 MRI lesions with maximal dimension ≤15mm and ISUP grade group 2-3 PCa will be recruited. Transperineal TMA of the prostate tumor(s) will be done with repeated ablations by a single microwave needle guided by MRI-Ultrasound fusion and OBT navigation. The primary outcome is any clinically significant PCa (csPCa) detected on biopsy of treated area(s) per patient at 12 months.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Peter Ka-Fung CHIU, PhD,MBChB
- 電話番号:35052625
- メール:peterchiu@surgery.cuhk.edu.hk
研究場所
-
-
-
Shatin、香港
- 募集
- Peter Ka-Fung CHIU
-
コンタクト:
- Peter Ka-Fung CHIU, PhD,MBChB
- 電話番号:35052625
- メール:peterchiu@surgery.cuhk.edu.hk
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria:
(i) Men aged ≥50 years old (ii) Life expectancy > 10 years upon recruitment (iii) Able to understand the trial and can provide informed and written consent, dated and signed before the enrollment and before any exam required by the trial (iv) Localized intermediate risk prostate cancer diagnosed on MRI-Ultrasound fusion targeted biopsy (v) Organ-confined prostate cancer on MRI (vi) PSA < 20 ng/mL (vii) 1-2 MRI visible lesion present with maximal tumor dimension ≤15mm, with targeted biopsy showing:
- ISUP grade group 2 or 3 PCa
- Systematic biopsies showing grade group 1-3 PCa just next to the MRI lesion is allowed
- Systematic biopsies showing grade group 1 PCa far away from the lesion is allowed
Exclusion criteria:
(i) Patients not fit for general or spinal anaesthesia (ii) Patients unfit for MRI exam or MR gadolinium contrast (e.g. estimated glomerular filtration rate (eGFR) of <50 ml/min) (iii) Patients with coagulopathy that cannot be corrected (iv) Patients on anticoagulants or antiplatelets that cannot be stopped (Low dose Aspirin, e.g. 80-100mg, is acceptable and no need to stop before or during TMA treatment) (v) Patients with previous treatment of prostate cancer (vi) Patients with prior pelvic radiotherapy for prostate cancer or other cancer (vii) Patients with maximal length of target lesion >15mm (viii) Patients with MRI lesion within 10mm from rectum or 10mm from sphincter on MRI (ix) Patients with >2 areas (MRI-visible or invisible) of prostate cancer (x) Patients with Gleason score 4+4 or any Gleason pattern 5 cancer (xi) Patients with systematic cores showing any Gleason 4 pattern PCa which are not adjacent to the target lesions (1 core of Gleason 3 pattern PCa on systematic cores in contralateral lobe is acceptable) (xii) Patients with definite extracapsular disease on imaging (prostate capsular contact without definite extra-capsular extension is acceptable) (xiii) Patients with bladder pathology including bladder stone or bladder cancer (xiv) Patients with known urethral stricture
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Targeted Microwave Ablation (TMA)
Targeted Microwave Ablation (TMA) for localized prostate cancer using organ based tracking (OBT) navigation |
Targeted microwave ablation (TMA) is a novel treatment developed for focal treatment of prostate cancer, and it is applied with precise navigation guidance under the organ-based tracking (OBT) mechanism. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The oncological control of prostate cancer
時間枠:At 12 months after treatment
|
Any clinically significant PCa (csPCa) detected on biopsy of treated area(s) per patient at 12 months after treatment, defined by: • ISUP grade group 2 or above PCa |
At 12 months after treatment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Clinically significant cancer detection on biopsy of each ablated MRI visible lesion
時間枠:At 12 months after treatment
|
Per-lesion analysis of csPCa detected on biopsy of any ablated areas at 12 months |
At 12 months after treatment
|
|
Cancer detection on biopsy of each ablated MRI invisible lesion
時間枠:At 12 months after treatment
|
Per-lesion analysis of any cancer detected on biopsy of any ablated areas at 12 months |
At 12 months after treatment
|
|
Out-of-field recurrence: Any cancer outside treated area on systematic biopsy
時間枠:At 12 months after treatment
|
Out-of-field recurrence: Any cancer outside treated area on systematic biopsy |
At 12 months after treatment
|
|
Common Terminology Criteria for Adverse Events (CTCAE) v5.0
時間枠:At 3 Month, 6 Month and 12 Month
|
Complications of treatment using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 |
At 3 Month, 6 Month and 12 Month
|
|
PSA change
時間枠:At baseline, 3 Month and 6 Month and 12 Month
|
PSA change after treatment |
At baseline, 3 Month and 6 Month and 12 Month
|
|
Urinary Symptoms after treatment
時間枠:At baseline, 3 Month, 6 Month and 12 Month
|
Urinary symptoms measured by IPSS score, score ranging from 0-35 (the higher the worse) |
At baseline, 3 Month, 6 Month and 12 Month
|
|
Sexual side effects after treatment
時間枠:At baseline, 3 Month, 6 Month and 12 Month
|
Sexual side effects, up to 1 year, measured by IIEF-5 score (ranging from 1-25), the lower the worse |
At baseline, 3 Month, 6 Month and 12 Month
|
|
Continence side effects after treatment
時間枠:At baseline, 3 Month, 6 Month and 12 Month
|
Continence side effects, up to 1 year, measured by EPIC-26 questionnaire, the lower score the worse |
At baseline, 3 Month, 6 Month and 12 Month
|
|
Common Terminology Criteria for Adverse Events (CTCAE) rectal toxicity
時間枠:At baseline, 3 Month, 6 Month and 12 Month
|
Rectal toxicity of treatment using Common Terminology Criteria for Adverse Events |
At baseline, 3 Month, 6 Month and 12 Month
|
|
Quality of life measured by ED-5Q-5Lquestionnaire
時間枠:At baseline, 3 Month, 6 Month and 12 Month
|
Quality of life measured by ED-5Q-5L questionnaire, the higher the score the better in quality of life |
At baseline, 3 Month, 6 Month and 12 Month
|
|
Quality of life in patients with prostate cancer measured by EPIC-26
時間枠:At baseline, 3 Month, 6 Month and 12 Month
|
Quality of life in patients with prostate cancer measured by EPIC-26 range 0-100, the higher score the better the quality of life |
At baseline, 3 Month, 6 Month and 12 Month
|
|
Quality of life measured by QLQ-C30
時間枠:At baseline, 3 Month, 6 Month and 12 Month
|
Quality of life measured by QLQ-C30, score 0-100, the higher the score the better in quality of life |
At baseline, 3 Month, 6 Month and 12 Month
|
協力者と研究者
協力者
捜査官
- 主任研究者:Peter Ka-Fung CHIU, PhD,MBChB、Chinese University of Hong Kong
出版物と役立つリンク
一般刊行物
- Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol. 2020 Jan;77(1):38-52. doi: 10.1016/j.eururo.2019.08.005. Epub 2019 Sep 5.
- Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, Tempany CM, Choyke PL, Cornud F, Margolis DJ, Thoeny HC, Verma S, Barentsz J, Weinreb JC. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019 Sep;76(3):340-351. doi: 10.1016/j.eururo.2019.02.033. Epub 2019 Mar 18.
- Stabile A, Orczyk C, Hosking-Jervis F, Giganti F, Arya M, Hindley RG, Dickinson L, Allen C, Punwani S, Jameson C, Freeman A, McCartan N, Montorsi F, Briganti A, Ahmed HU, Emberton M, Moore CM. Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. BJU Int. 2019 Sep;124(3):431-440. doi: 10.1111/bju.14710. Epub 2019 Mar 18.
- Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019 Apr;10(2):63-89. doi: 10.14740/wjon1191. Epub 2019 Apr 20.
- Barry Delongchamps N, Schull A, Anract J, Abecassis JP, Zerbib M, Sibony M, Jilet L, Abdoul H, Goffin V, Peyromaure M. Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial. PLoS One. 2021 Jul 14;16(7):e0252040. doi: 10.1371/journal.pone.0252040. eCollection 2021.
- Durand M, Barret E, Galiano M, Rozet F, Sanchez-Salas R, Ahallal Y, Macek P, Gaya JM, Cerruti J, Devilliers H, Loeffler J, Amiel J, Vallancien G, Cathelineau X. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer. BJU Int. 2014 Jan;113(1):56-64. doi: 10.1111/bju.12370. Epub 2013 Oct 31.
- Shah TT, Peters M, Eldred-Evans D, Miah S, Yap T, Faure-Walker NA, Hosking-Jervis F, Thomas B, Dudderidge T, Hindley RG, McCracken S, Greene D, Nigam R, Valerio M, Minhas S, Winkler M, Arya M, Ahmed HU. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol. 2019 Jul;76(1):98-105. doi: 10.1016/j.eururo.2018.12.030. Epub 2019 Jan 9.
- Chiu PK, Chan CH, Yee CH, Lau SY, Teoh JY, Wong HF, Lo KL, Yuen TY, Hung HY, Cho CC, Ng CF. Transperineal Targeted Microwave Ablation (TMA) of localized prostate cancer guided by MRI-Ultrasound fusion and organ-based tracking: a pilot study. Prostate Cancer Prostatic Dis. 2023 Dec;26(4):736-742. doi: 10.1038/s41391-022-00577-8. Epub 2022 Jul 14.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。